# **Curriculum Vitae**

Date Prepared: September 19, 2014

Name: Sareh Parangi, M.D.

Office Address:

Wang Ambulatory Center 460 15 Parkman Street Boston, MA 02114

**Home Address:** 

200 Brookline Street Newton, MA 02459

**Work Phone:** (617) 643-4806

Work E-Mail: sparangi@partners.org

**Work FAX:** (617) 643-4802



Year	Degree (Honors)	Field of Study	Institution
			Barnard College,
1986	B.A.	Biology	Columbia University,
			NY
			Columbia University
1990	M.D.	Medicine	College of Physicians
			& Surgeons

#### **Postdoctoral Training**

i ostaoctorar i rai	8		
Year	Title	Specialty/Discipline	Institution
1990-1991	Intern	Surgery	Univ. Of California,
			San Francisco
1991-1998	Resident	Surgery	Univ. of California,
			San Francisco
1992-1995	Fellow	Molecular Medicine	Univ. of California,
			San Francisco
1994-1995	Research Fellow	Surgical Research	Children's Hospital,
		_	Boston
1993-1995	Fellow	Research	Whitehead Institute,
			Boston

### **Faculty Academic Appointments**

<b>Year</b> 1998-2001	Academic Title Instructor	<b>Departme</b> Surgery	ent	Academic Institution Harvard Medical
2001-2010	Assistant Professor	Surgery		School Harvard Medical School
2010-	Associate Professor	Surgery		Harvard Medical School
Hospital or Affiliate	d Institution Appointme	ents:		
Year	Position Title	Departme	nt	Institution
1998-	Staff Surgeon	Surgery		Beth Israel Deaconess Medical Center
2000-	Staff Surgeon	Surgery		Mount Auburn Hospital
2001-	Surgical Director	Surgery		Beth Israel Deaconess Medical Center, Thyroid Center
2002-	Staff Surgeon	Surgery		Needham Campus of Beth Israel Deaconess
2007-	Staff Surgeon	Surgery		Medical Center New England Baptist Hospital
2007-	Staff Surgeon	Surgery		Massachusetts General Hospital, Associate Visiting Surgeon
Major Administrati	ve Responsibilities:			Visiting Burgeon
Year	Position Title		Institution	
2000-2006	Director of Surgical Gra	and Rounds	Beth Israel N Center	Medical Deaconess
2000-2006	Director of General Surg Scheduling	gery Staff	Beth Israel N Center	Medical Deaconess
2001-2004	Surgical Director			roid Nodule Clinic
2005-2007	Surgical Director		BIDMC Thy	roid Center
2001-2007	Attending Surgeon		BIDMC Thy Center's	roid and Parathyroid
2013-current	Fellowship Director		MGH Endoc Fellowship	erine Surgery
<b>Committee Service:</b>				
Year	Name of Committee		Institution	
2000-2003	Member of Housestaff E Committee		Center	Medical Deaconess
2002-2007	Member of Subcommitte Women, Committee for Development		Beth Israel M Center	Medical Deaconess
2004-2005 2012-2014	Technologies Liaison Co Temporary Member of S		BIDMC National Ins	titute of Health
2012-2014	Review Panel for 4 Stud ICER, MCE, P01, SPOR	ly Sections:	rvational ins	titute of Health
2012	Mentor member in Prog	ram in	Massachuse	tts General Hospital

# Faculty Development and Mentoring

2011-2013 Grant Reviewer

Italian Association for Cancer Research (AIRC)

Professional Societies: Years of Membership 1998- 1998- 1999-2002 2000- 2001- 2007- 2001- 2002- 2002-	Society Name Fellow, American College of Surgeons Member Naffzinger Society Association for the Advancement of Science American Association for Cancer Research Fellow of the American College of Surgery Member Scholarships Committee Member of the Massachusetts Chapter of the American College of Surgeons Member Society for Surgical Oncology Member American Association of Endocrine
• 2008-2012	<ul><li>Surgeons</li><li>Member of Scholarship Committee</li></ul>
• 2010-2013	<ul><li>with grant review responsibilities</li><li>Chair, Education and Research Committee</li></ul>
• 2010-2013	<ul> <li>Council Member</li> </ul>
• 2013-2016 2002-	<ul> <li>Member Information Technologies Committee</li> <li>Member International Association of Endocrine Surgeons</li> </ul>
2002-	Member American Thyroid Association
• 2005-2009	<ul> <li>Member of the Membership committee</li> </ul>
• 2010-	<ul> <li>Member of the ATA Thyroid Research Funding Task Force</li> </ul>
2004-	Member Boston Surgical Society
2006-	Member of The Association of Women Surgeons
• 2006-2008	<ul> <li>Vice Chair AWS Grants &amp; Awards Committee</li> </ul>
• 2008-2010	<ul> <li>Chair of the AWS Grants &amp; Awards</li> <li>Committee with grant review</li> </ul>
• 2010-2012	responsibilities  Chair Database Development
2014-2016	committee  Treasurer
2011- 2012-	Member Society Of University Surgeons Member International Thyroid Oncology

# Group

• Member of Anaplastic thyroid cancer taskforce

2006
• 2012-2015

• Member American Association of Clinical Endocrinologist

• Member of Thyroid Scientific Committee

Member International Society of Oncoplastic Endocrine Surgeons

• 2013-2015

• Member of the Board Member Surgical Biology Club

### **Editorial Activities**

Year	Role	Journal Name
2003-	Ad Hoc Reviewer	Clinical Cancer Research
2004-	Ad Hoc Reviewer	Cancer Research
2005-	Ad Hoc Reviewer	Molecular Therapeutics
2005-	Ad Hoc Reviewer	Surgery
2005-	Ad Hoc Reviewer	Cancer
2005-	Ad Hoc Reviewer	Journal of Surgical Oncology
2006-	Ad Hoc Reviewer	World Journal of Surgery
2011-	Ad Hoc Reviewer	Laryngoscope
2012-	Ad Hoc Reviewer	Cancer Immunology
		Immunotherapy
2011-	Ad Hoc Reviewer	British Journal of Cancer
2012-	Ad Hoc Reviewer	Thryoid
2013-	Member of Editorial Board	VideoEndocrinology (ATA journal)

### **Honors and Prizes**

Year	Name of Honor/Prize	Awarding Organization	Achievement for which awarded
1986	Magna Cum laude	Phi Beta Kappa	Academic achievement
1987	Deans NIH	Columbia University College of Physicians and Surgeons	Research Award
1990	S.W. Rover and L. Rover Award	Columbia University College of Physicians and Surgeons	Physiology and Cellular Biophysics
1991 1992	Burroughs Welcome Molecular Medicine	Burroughs Welcome UCSF	Research Award Research Fellowship

1993 1997	Naffzinger Surgical Alpha Omega Alpha Honor Society	UCSF Medical Students	Research Award Student teaching award for best resident teacher
2009	Eleanor and Miles Shore 50 <sup>th</sup> year anniversary fellow award winner	Harvard Medical School and MGH Department of Surgery	Faculty Development

# **Report of Funded and Unfunded Projects**

Year(s) fundedRole on ProjectFunding SourceTotal direct cost1992-1995Principal InvestigatorBurroughs Wellcome\$30,000 per yearResearch Award for Molecular Medicine1999-2001Title: Antiangiogenic therapy in a transgenic model carcinogenesis Investigate combinatorial antiangiogenic therapies in transgenic islet cell tumors of the pancreas1999-2001Principal InvestigatorMedical Medical Medical Medical Medical Foundation/Dolphin Trust Grant\$100,000Title: Antiangiogenic therapy, a novel therapy for pancreatic caner Looked at the role of antiangiogenic therapies in orthotopic mouse models of pancreatic cancer2001-2003Principal Investigator American College of Surgeons Faculty Research Fellowship\$80,000Title: Antiangiogenic gene therapy in a mouse model of pancreatic	Past – Funded Project	S		
Research Award for Molecular Medicine  Title: Antiangiogenic therapy in a transgenic model carcinogenesis Investigate combinatorial antiangiogenic therapies in transgenic islet cell tumors of the pancreas  1999-2001 Principal Investigator Medical \$100,000 Foundation/Dolphin Trust Grant  Title: Antiangiogenic therapy, a novel therapy for pancreatic caner Looked at the role of antiangiogenic therapies in orthotopic mouse models of pancreatic cancer  2001-2003 Principal Investigator American College of \$80,000 Surgeons Faculty Research Fellowship  Title: Antiangiogenic gene therapy in a mouse model of pancreatic	Year(s) funded	<b>Role on Project</b>	<b>Funding Source</b>	<b>Total direct cost</b>
Molecular Medicine  Title: Antiangiogenic therapy in a transgenic model carcinogenesis Investigate combinatorial antiangiogenic therapies in transgenic islet cell tumors of the pancreas  1999-2001  Principal Investigator  Medical Foundation/Dolphin Trust Grant  Title: Antiangiogenic therapy, a novel therapy for pancreatic caner Looked at the role of antiangiogenic therapies in orthotopic mouse models of pancreatic cancer  2001-2003  Principal Investigator American College of \$80,000 Surgeons Faculty Research Fellowship  Title: Antiangiogenic gene therapy in a mouse model of pancreatic	1992-1995	Principal Investigator		\$30,000 per year
Title: Antiangiogenic therapy in a transgenic model carcinogenesis Investigate combinatorial antiangiogenic therapies in transgenic islet cell tumors of the pancreas  Principal Investigator Medical \$100,000 Foundation/Dolphin Trust Grant  Title: Antiangiogenic therapy, a novel therapy for pancreatic caner Looked at the role of antiangiogenic therapies in orthotopic mouse models of pancreatic cancer  Principal Investigator American College of \$80,000 Surgeons Faculty Research Fellowship Title: Antiangiogenic gene therapy in a mouse model of pancreatic				
Investigate combinatorial antiangiogenic therapies in transgenic islet cell tumors of the pancreas  1999-2001  Principal Investigator  Medical  Foundation/Dolphin  Trust Grant  Title: Antiangiogenic therapy, a novel therapy for pancreatic caner Looked at the role of antiangiogenic therapies in orthotopic mouse models of pancreatic cancer  2001-2003  Principal Investigator  American College of \$80,000  Surgeons Faculty  Research Fellowship  Title: Antiangiogenic gene therapy in a mouse model of pancreatic				
tumors of the pancreas  Principal Investigator Medical \$100,000  Foundation/Dolphin  Trust Grant  Title: Antiangiogenic therapy, a novel therapy for pancreatic caner Looked at the role of antiangiogenic therapies in orthotopic mouse models of pancreatic cancer  2001-2003 Principal Investigator American College of \$80,000  Surgeons Faculty Research Fellowship  Title: Antiangiogenic gene therapy in a mouse model of pancreatic				
Principal Investigator Medical \$100,000 Foundation/Dolphin Trust Grant  Title: Antiangiogenic therapy, a novel therapy for pancreatic caner Looked at the role of antiangiogenic therapies in orthotopic mouse models of pancreatic cancer  Principal Investigator American College of \$80,000 Surgeons Faculty Research Fellowship Title: Antiangiogenic gene therapy in a mouse model of pancreatic			al antiangiogenic therapie	s in transgenic islet cell
Foundation/Dolphin Trust Grant  Title: Antiangiogenic therapy, a novel therapy for pancreatic caner Looked at the role of antiangiogenic therapies in orthotopic mouse models of pancreatic cancer  2001-2003  Principal Investigator American College of \$80,000 Surgeons Faculty Research Fellowship Title: Antiangiogenic gene therapy in a mouse model of pancreatic				****
Trust Grant  Title: Antiangiogenic therapy, a novel therapy for pancreatic caner Looked at the role of antiangiogenic therapies in orthotopic mouse models of pancreatic cancer  2001-2003  Principal Investigator American College of \$80,000 Surgeons Faculty Research Fellowship  Title: Antiangiogenic gene therapy in a mouse model of pancreatic	1999-2001	Principal Investigator		\$100,000
Title: Antiangiogenic therapy, a novel therapy for pancreatic caner Looked at the role of antiangiogenic therapies in orthotopic mouse models of pancreatic cancer  2001-2003 Principal Investigator American College of \$80,000 Surgeons Faculty Research Fellowship Title: Antiangiogenic gene therapy in a mouse model of pancreatic				
Looked at the role of antiangiogenic therapies in orthotopic mouse models of pancreatic cancer  2001-2003 Principal Investigator American College of \$80,000 Surgeons Faculty Research Fellowship Title: Antiangiogenic gene therapy in a mouse model of pancreatic		TD'd A d' ' ' d		,·
models of pancreatic cancer  2001-2003  Principal Investigator American College of \$80,000  Surgeons Faculty  Research Fellowship  Title: Antiangiogenic gene therapy in a mouse model of pancreatic				
2001-2003  Principal Investigator American College of \$80,000  Surgeons Faculty  Research Fellowship  Title: Antiangiogenic gene therapy in a mouse model of pancreatic				orthotopic mouse
Surgeons Faculty Research Fellowship <u>Title</u> : Antiangiogenic gene therapy in a mouse model of pancreatic	2001-2003			000 082
Research Fellowship <u>Title</u> : Antiangiogenic gene therapy in a mouse model of pancreatic	2001-2003	Timelpar investigator		\$60,000
<u>Title</u> : Antiangiogenic gene therapy in a mouse model of pancreatic				
1		Title: Antiangiogenic ge		odel of pancreatic
cancer		cancer		out of panorouse
Tested Adenoassociated adenoviral gene therapy vectors in pancreatic		Tested Adenoassociated	adenoviral gene therapy	vectors in pancreatic
cancer.				•
2001-2003 Co-Investigator American Cancer	2001-2003	Co-Investigator	American Cancer	
Society Grant				
<u>Title</u> : Role of IGF I Receptor in Pancreatic Cancer				
Looked at the role of IGF-1 receptor in pancreatic cancer invasion				c cancer invasion
2002-2007 Co-PI on Project 3 National Cancer	2002-2007	Co-PI on Project 3		
Institute		F11 P01 NGV P		
Title: P01, NCI-Program Project Grant, Temporal and Spatial Regulation				
of Angiogenesis, Project 3: "Inhibition of Angiogenesis by			3: "Inhibition of Angiog	genesis by
Thrombospondin – 1"  Locked at the role of TSP 1 in and the lied an enteric and noncreation			D 1 in and othelial anome	seis and nanamatic
Looked at the role of TSP-1 in endothelial apoptosis and pancreatic tumor regression			P-1 in endotherial apopto	osis and pancreatic
2002-2007 Principal Investigator National Cancer \$122,000 per year	2002 2007	•	National Cancer	\$122,000 per year
Institute 1 K08	2002-2007	Timelpai investigator		\$122,000 per year
CA88965-01A1				
<u>Title</u> : Antiangiogenic therapy of pancreatic cancer		Title: Antiangiogenic the		r
Looked at the role of various antiangiogenic therapies both in vitro and				
in vivo				•

2004-2006	Principal Investigator	American Thyroid	\$25,000
		Assoc. Thy Ca Award	l
	<u>Title</u> : Antiangiogenic Therapy of Thyroid Cancer		
	Testing of antiangiogeni	ic therapies in a novel a	nimal model of papillary
	thyroid cancer	_	

Current – Funaea Projects	
Year(s) funded	

Year(s) funded	Role on Project	<b>Funding Source</b>	<b>Total direct cost</b>
2008-2013	Co-Principal	Amelia Peabody Charitable Foundation	
	Developed and used Tis	Repository and Molecula sue Banking protocols an m patients undergoing end	d database for banking
2009-2013	Principal Investigator	Polsky Family Fund	\$50,000/year
	<u>Title</u> : BRAF and thyroid Investigate the role of F invasion and metastasis	l cancer invasion BRAF V600 mutation in t	hyroid cancer cell
2009-2010	Principal Investigator	Eleanor and Miles Shore 50 <sup>th</sup> year HMS/MGH Department of Surgery Faculty Development Award	\$50,000
		and thyroid cancer invasi f BRAF on in vivo thyroi	
2009-2013	Co-investigator	NIH-NCI R01 R01CA130895-01A2 (PI, Lawler)	186,750 per year
		ogenesis by Thrombospo nelial apoptosis when con	
2010-2015	Principal Investigator	NIH-NCI R01 1R01CA149738- 01A1	250,000 per year
	<u>Title</u> : The role of BRAF	mutation in thyroid canc	eer invasion
2010 - Current	Principal Investigator	Quest Diagnostics	65,000 total cost
	<u>Title</u> : Use of a novel Th	nyroglobulin assay in pati	ents with thyroid cancer
2012-2014	Principal Investigator	NCCN	100,000 for two years
		ing of Resistance to BR del of thyroid cancer pr	

# Unfunded Projects: Clinical Research:

	Role on Project Sub Investigator Title: Phase 3 Trial of A dysfunction- completed	Funding Source Adolor/GlaxoSmithKline Corporation lyimopan in Postoperative Ileus and Opioid bowel
2003 –2007	Reaction (MRT – PCR	BIDMC Department of Pathology & Reverse Transcriptase Polymerase Chain &) and BARCODE Analysis to Assist the Diagnosis Fine Needle Aspirations
2004 -2006	Title: Use of PET/CT s Demonstrated novel us patients with indeterms completed	BIDMC Clinical funds scanning in patients with thyroid nodules. se of PETCT scanning as a diagnostic tool in inate fine needle aspirations of thyroid nodules  MGH Departmental support
2006 – 2008	Principal Investigator  Title: Intraoperative R	BIDMC Departmental support tapid Parathyroid Hormone Assay, completed
2007 – 2008		MGH Departmental support dity and mortality rates in octogenarians gery at Massachusetts General Hospital,
2008 – 2009	Co- Învestigator  Title: Studying use of dissection for papillary	MGH Departmental support surgical drains in patients undergoing neck cancer at the Massachusetts General Hospital,
2009 – 2011	completed Principal Investigator	MGH Departmental support
2005 - Current	Title: Calcitonin secre Co-Investigator	etion in small Medullary Carcinomas, completed MGH Departmental support
2009 – Current	and urine of patients w Principal Investigator	we and negative regulators of angiogenesis in blood with pancreatic cancer  MGH Departmental support
2009 – Current	thyroid and surgery in Principal Investigator	

support

Title: BRAF mutation status in good prognosis vs poor prognosis

Level of effort

Contact time: 46 Hours per

Contact time: 6 hours per year

Role: Preceptor for 10 -15 HMS II students per yr

papillary cancers

Title

Principal Investigator MGH Departmental

Basic Science Review,

support

## **Report of Local Teaching and Training**

Year

1996 - 1998

1998-2000

Teaching at the University of California, San Francisco

24 Supriced Projector	preparation of fellow residents at the University of California, San Francisco for the Surgery In-service (ABSITE) exam.	year Role: Course Organizer
24 Surgical Residents		
1997 – 1998	Clinical Surgical Lecture, taught one hour clinical correlation lectures to UCSF third year medical students, once per week. Won resident teaching award for 1997	Contact time: 2 hours per year
	4 UCSF third year medical students	Role: Lecturer
Teaching at HMS: Medical S	School Courses, Harvard Medical	School
Year	Title	Level of effort
1998-2002	Introduction to Clinical Medicine (Patient-Doctor II)	Contact time: 18 hrs. per year
	for physical diagnoses, history talking, and oral presentations, introduction to the operating room	Role: Preceptor for 3 HMS II Students per year
1998-2000	Advanced Biomedical Sciences Course – Biology of Solid Tumor progression	Contact time: 6 hours per year Role: Preceptor for 8 HMS II students per year
1998-2000	Advanced Biomedical Sciences Course – Biology of Solid Tumor progression	Contact time: 6 hours per year

Core Clerkship in Surgery Basics in suturing techniques

1998 – 2006	Surgical Clerkship Examination at BIDMC	Contact time:8 hours per year Role: Examiner two times yearly, 4 medical students each 4 students per year
1998 – 2007	Core Clerkship in Surgery at BIDMC	Contact time: 100 hours per yr Role:Preceptor for on HMS III student at a time for one on one teaching and mentoring during their 4 weeks surgery general surgery rotation, including direct teaching during outpatient care of the surgical patient and in the operating room. Concentrated effort on teaching medical students about surgical diseases of the endocrine organs
2000 –2007	Core Clerkship in Surgery for HMS students at BIDMC and the BWH	Contact time: 8 hours per year Role: Lecturer on Hyperthyroidism and Thyroid Cancer for 16 HMS III students per year Two hour session, 4 times per year
2000 – 2007	Core Clerkship in Surgery for HMS Students at BIDMC and the BWH	Contact time: 8 hours per year Role: Lecturer on Hyperparathyroidism for 16 HMS students per year
2004 – 2006	Core Clerkship in Surgery/Live Video Teaching at BIDMC and the BWH, Live Broadcast Thyroid and Parathyroid surgery Live	Contact time: 4 hours per year Role: Lecturer for 12 HMS III students
2004 – 2006	Core Clerkship in Surgery/Live Video Teaching at BIDMC and	Contact time: 2 hours per year Role: Lecturer for 12 HMS III

the BWH, Live Broadcast inguinal hernia surgery

students

2007 - Current

Core Clerkship in Surgery for HMS students at Massachusetts General Hospital Baker 7 service Contact time: 42 hours per yr Role: Attending surgeon on Endocrine surgery service. Teaching and mentoring during their 4 weeks surgery general surgery rotation, including direct teaching during outpatient care of the surgical patient and in the operating room. Concentrated effort on teaching medical students about surgical diseases of the endocrine organs. For 6 HMS IV student per year

2012-2013

Vear

Pursuing Inquiry in Medicine (PIM) Course

Contact time: 2 hours per

week

Role: Mentor for one HMS/HDS student to work on preparing a HMS Scholars in Medicine project for summer of 2013 on development of an orthotopic

medullary thyroid cancer

mouse model.

Level of effort

#### Formal Teaching of Residents, Clinical Fellows and Research Fellows

Title

1998 – 2002	Advanced Trauma Live Support Course	Contact time: 16 hours per year Role: Lecturer and Hand on Instructor for 15 Residents, faculty, and outside students
2000 – 2007	Attending Surgeon, Thyroid Nodule Clinic, BIDMC. Have role in teaching ultrasound and fine needle aspiration technique in the care of patients with diseases of the thyroid in a multidisciplinary fashion	Contact time: 2 hours of direct teaching per week Role: Attending Surgeon for One medicine resident, one endocrine fellow per year

2000 – 2006	Director of Surgical Grand Rounds, BIDMC. Total time spent with each resident on preparation 10 min to three hrs.	Contact time: 18 hours per yr Role: Organize a total of 36 yearly talks by surgical residents or surgical fellows. Help prepare residents choose an appropriate topic and mentor for a 20 minute talk to surgical ground rounds. Each talk is reviewed prior to presentation for content. Encourage residents to publish these talks. For 36 BIDMC surgical residents and surgical fellows
2002 – 2007	BIDMC Core Curriculum Conference	Contact time: 2 hours per year Hyperparathyroidism, adrenal tumors; 3 hour interactive lectures/case presentations Role: Lecturer on hyperparathyroidism 28 BIDMC Surgical Residents
2002 – 2007	BIDMC Core Curriculum Conference	Contact time: 2 hours per year Role: Lecturer on Thyroid nodules and Thyroid cancer 28 BIDMC surgical residents
2002 – 2007	BIDMC Core Curriculum Conference	Contact time: 2 hours per year Role: Lecturer on Pheochromocytomas and other adrenal tumors 28 BIDMC surgical residents
2003	Clinical Pathologic Correlation Lecture Hurthle cell tumors of the Thyroid	Contact time: 2 hours Role: Lecturer with Dr. Sharifi of pathology 12 BIDMC surgical residents
2003	Clinical Pathologic Correlation Lecture Hurthle cell tumors of the Thyroid	Contact time: 2 hours Role: Lecturer with Dr. Sharifi of pathology 12 BIDMC surgical residents
2005 – 2007	Core Curriculum Conference	Contact time: 2 hours per year Role: Lecturer on neck masses

# 12 BIDMC surgical residents

2005	BIDMC Endocrine Curriculum Retreat	Contact time: 4 hours total Role: Curriculum development. Helped the BIDMC Endocrine Division (Department of Medicine) develop an accurate and up to date curriculum involving surgical treatment of endocrine diseases and the use of ultrasound and fine needle aspiration techniques by medicine residents doing their endocrine rotation and by endocrine fellows
2005 – 2007	Seminars in operative skills at BIDMC Surgical Skills Lab	Contact time: 6 hours per year Prep. time: 2 hours per year Role: Lecturer and had on demonstration of Head and Neck Ultrasound: lecture, case presentation and hands on teaching of ultrasound and ultrasound guided fine needle aspiration for a mixed audience of 8 HMS students, 25 surgical residents and 3 endocrinology fellows
2005	BIDMC Endocrinology Clinical conference	Contact time: 1 hours per year Role: Mentor an endocrine fellow to present talk on Neurofibromatosis and Parathyroid cancer 3 BIDMC medicine residents 6 Endocrine fellows
2006	BIDMC Pathology Core Curriculum Conference	Contact time: 2 hours per year Role: Lecturer on Animal models of tumor progression 8 BIDMC pathology residents
2007 – Present	MGH Baker 7 Endocrine Surgery Core Curriculum Conference	Contact time: 6 hours per year Role: Lecturer on Thyroid Ultrasound, normal neck

anatomy

3 MGH Surgical Residents

and interns

2008 Diabetes Neuroendocrine

Thyroid Curriculum

Conference

Contact time: 1 hours per year Role: Lecturer on Surgery of the thyroid and parathyroid

glands

8 MGH Endocrinology fellows and Endocrine Surgery Fellows

2010 MGH Surgical Resident

Didactic Teaching curriculum

Contact time: 6 hours per year Role: Lecturer on Work up of

Thyroid Nodules and Thyroid

Ultrasound

32 MGH Surgical Residents

# **Clinical Supervisory and Training Responsibilities**

<b>Year</b> 1998 – 2007	Type of Responsibility BIDMC General Surgery team.	Institution Beth Israel Deaconess Medical Center	Level of Effort Operating room teaching Three surgical residents, Twelve months per year. Ten hours of direct teaching per week including operating room teaching
2000 - 2007	Attending Surgeon Thyroid Nodule Clinic	Beth Israel Deaconess Medical Center	One (1) Resident, One (1) fellow per year; 6 hours of direct Teaching per month, including performing and teaching ultrasound and fine needle aspiration technique to medical residents, surgical resident as well as the Endocrine fellow, 12 (12) months per year
2001 -2004 2005 -2007	Surgical Director and supervising attending	BIDMC Thyroid Center, Thyroid Nodule Clinic	8 hours per month, Twelve (12) months per year, Scheduling of clinic, Clinic space allocation, Thyroid

Center database supervision, purchase and maintenance of Ultrasound for use at the Thyroid Center, Maintenance of updated print and web based material for patient education used at the thyroid center. One (1) fellow per year; 6 residents per year, 8 hours of direct Teaching per week, including work up of endocrine surgery patients as well as performing thyroid, parathyroid and adrenal surgical procedures, teaching ultrasound and details

on performance of fine needle aspiration technique 12 months

2007 - current Clinical Supervisor for

two Baker 7 Surgical residents and one **Endocrine Surgery** 

Fellow

Massachusetts General Hospital

Laboratory and Other Research Supervisory and Training Responsibilities

Year	Type of Responsibility	Institution	Level of Effort
1998 - current	Laboratory Principal	BIDMC	One (1) research
	Investigator, Surgical	MGH	assistant, and One postdoctoral fellow,
			Twenty (20) hours per week including daily
			didactic meetings

### Formally Supervised Clinical and Research Trainees

2003-2006	Melanie Edwards, MD Surgical Resident at BIDMC	Currently an Attending Thoracic Surgeon, LSU
	Served as formal academic ad	visor
2003-2006	Amy Evenson, MD	Currently an Attending Surgeon,
	Surgical Resident at BIDMC	Transplant Surgery BIDMC
	Served as formal academic ad	visor, wrote 2 papers together
2004-2006	Jamie Mitchell, MD	Currently an Attending Surgeon,
	Surgical Resident at BIDMC	Endocrine Surgery and General

# Surgery at the Cleveland Clinic

Assistant Professor of

Pathology

Postdoctoral research fellow in my laboratory, working on BRAF inhibitors in thyroid cancer, published extensively and now has

Served as unofficial academic advisor, wrote 4 papers together

2004-2006	Melanie Goldfarb, MD Surgical Resident at BIDMC	Assistant Professor of Surgery, University of Southern California, Endocrine Surgeon
	Served as unofficial academic a	
2004-2006	Caitlin Connolly, BA	Medical student at the University of Massachusetts, Medical School
2004-2007	XueFeng Zhang,MD PhD	Assistant Professor of Pathology at Duke University
	Postdoctoral fellowship, 7 basic	science papers
2005-2006	Lingge Lu, MD, PhD	Postdoctoral fellow, Children's Hospital Boston, Division of Plastic Surgery
	Research technician, 2 basic scientification and the s	ence papers, went onto medical school
2007-2009	Michal Mekel, MD	Attending Surgeon BAM BAM Hospital, Tel Aviv, Israel
	Endocrine Surgery Fellow, 3 ba	sic science and clinical papers Have
	helped her prepare and submit 3	research grants
2008- current	Carrie Lubitz MD	Assistant surgeon at MGH, Harvard Medical School
	<b>.</b> .	work together has yielded one clinical
		Have helped her prepare and submit 3
2008-2011	research grants, including an NI Sushruta Nagarkatti, MD	Thoracic surgery non accredited
2006-2011	Susmuta Ivagarkatti, IVID	Fellow at BWH
	Looking at Urinary Biomarkers	of malignancy, have submitted two
		ther, and published one paper so far. He
	was accepted into surgical resid	ency in a preliminary position at the
	University of Connecticut in Ha	artford
2008- 2010	Maria Hassan,BA	Database supervisor
	Endocrine Surgery Database De	
1.4	medical school at Wayne State i	in Michigan, and is now a resident in
internal medicine	Motthaw A Naha MD	DWII Endomino Cumomy Instructor in
2008- 2010	Matthew A Nehs MD	BWH Endocrine Surgery, Instructor in Surgery
		llow, supervised his T32 funded research ted at the AAES meetings and he has
	submitted multiple papers.	ned at the AALS incettings and he has
2007 2011		

Carmelo Nucera MD PhD

2007-2011

# An R01 and an R21.

2011-2012 family practice residency at B	Two abstracts, published one pa	Medical student ent, worked in my lab and presented per. Accepted into his first choice
2012-2013	• •	Assistant Professor of Surgery, Johns Hopkins University work together has yielded one clinical elped him prepare and submit papers new faculty
2011-current	Shohreh Varmeh PhD Postdoctoral research fellow in m repair pathways in thyroid cancer	Postdoctoral fellow ny laboratory, working on DNA damage r
2011-current	Pierre Vanden Borre PhD  Postdoctoral research fellow in metastasis pathways in thyroid ca	•
2013-current  2011-2013		th to medical School, currently
2011-2012	Dana Yip, MD PhD	Assistant Professor of Surgery, Stanford University

Endocrine Surgery Fellow, Our work together has yielded one clinical presentation and one abstract. Helped her prepare and submit papers and plan her next career steps

2012-2013	Travis McKenzie	Attending in Endocrine Surgery Mayo Clinic
	<b>Endocrine Surgery Fellow</b>	

# Formal Teaching of Peers (CME and other Educational Courses):

## **Local Invited Presentations**

Year	Title of Presentation	Type of Presentation
2000	Tumor Progression and	Beth Israel Deaconess Medical
	angiogenesis	Center, Surgical Grand Rounds
2000	Animal models of pancreatic	Beth Israel Deaconess Medical
	cancer	Center, Radiology Research
2002	Imaging angiogenesis in an	Beth Israel Deaconess Medical
	orthotropic animal model of	Center, Radiology Research
	pancreatic cancer	Seminar 4/02
2003	Asked to speak as part of a	American Medical Women's
2004	panel of Women in Academics	Association (AMWA)
	as an Academic surgeon	Sponsored Event HMS 12/03
2005		and 11/04
2005	Minimally Invasive	Mt. Auburn Hospital,
	Parathyroid and Adrenal	Cambridge, MA Surgical
2005	Surgery	Grand Rounds
2005	Minimally Invasive Endocrine	Deaconess Glover Hospital
	Surgery	Medical Grand Rounds,
		Needham, MA
2005	Novel Horizons in Thyroid	Invited Speaker at Deaconess
	Cancer	Glover Hospital Medical
		Grand Rounds, Needham, MA
2008	Incidental Thyroid Nodules	Speaker at New England
	•	Baptist Hospital, Medicine
		Grand Rounds, Boston, MA
2008	Thyroid Surgery, More or Less	Speaker at the Harvard
	Surgery	Advances in Cancer

		Management for the Surgeon Course, Boston, MA
2008	Office Based Ultrasound, Obstacles to Getting Started	Speaker at the Harvard Course on Surgery of the Thyroid and Parathyroid Glands, Boston, MA
2009	Thyroid Surgery, Questions frequently asked by patients	Speaker at MGH: Diabetes, Thyroid, Neuroendocrine Conference, Boston, MA
2009	Thyroid nodules, thyroid cancer and indications for surgery	Speaker and panelist at Mt. Auburn Hospital Medicine Grand Rounds Boston, MA
2009	Recent Advances in parathyroid surgery	Speaker and panelist at the Harvard Advances in Cancer Management for the Surgeon Course, Boston, MA
2010	Parathyroid surgery: Have we made a simple procedure more complicated?	Speaker at Mt. Auburn Hospital Surgical Grand Rounds Boston, MA
2010	Preoperative Sestamibi scanning	Speaker at the Harvard Course on Surgery of the Thyroid and Parathyroid Glands, Boston, MA
2012	Preoperative Sestamibi scanning	Speaker at the Harvard Course on Surgery of the Thyroid and Parathyroid Glands, Boston, MA

# Report of Regional, National and International Invited Teaching and Presentations

# **Regional Invited Presentations and Courses**

<b>Year</b> 1999	Title of Presentation Angiogenesis and Pancreatic Tumor Progression	<b>Type of Presentation</b> New England Surgical Society Spring Meeting, 5/8/99
2000	New and Old in the treatment of primary hyperparathyroidism	Caritas Good Samaritan Medical Center 5/24/00
2005	Incidentally detected thyroid nodules, an epidemic	Invited speaker at Milton Hospital Milton, MA
2005	Incidentally detected thyroid nodules, an epidemic	Speaker at St. Luke's Hospital, New Bedford, MA
2006	The epidemic of incidentally detected thyroid nodules"	Speaker at Beverly Hospital, Beverly, MA
2009	Planning your career in academic surgery	Speaker at Career Development Day for Women

# **National Invited Presentations and Courses**

1994	Chromosomal deletions in early stages of tumor progression: Search for a novel tumor suppressor or angiogenesis suppressor	Invited Speaker, American College of Surgeons, Surgical Forum October 1994 Chicago, IL
1995	gene Chromosomal deletions in early stages of tumor progression: Tumor suppressor loci on mouse chromosomes 9 and 16 are lost at distinct stages of tumorigenesis in a transgenic model of islet cell	Invited to give podium presentation at <i>Society for University Surgeons</i> , Colorado, Jan 1995
1995	carcinoma Treatment of transgenic mice with a regimen of angiogenesis inhibitors impairs tumor development	Invited to give podium presentation at <i>American Association for Cancer Research</i> , Toronto, Canada March 1995
1999	Antiangiogenic therapy with thrombospondin reduces tumor volume in an orthotopic model of pancreatic cancer in SCID mice	Invited Speaker, American College of Surgeons, Surgical Forum October 1999 San Francisco, CA
2001	Gene therapy with a recombinant adenoassociated virus (rAAV) in an orthotopic model of pancreatic cancer in SCID mice	Invited Speaker, American College of Surgeons, Surgical Forum October 2001 New Orleans, LA
2002	Requirement of Insulin Like Growth Factor –I for Autocrine-induced Proliferation, Invasion and VPF/VEGF Expression in Pancreatic carcinoma	Invited Speaker, American College of Surgeons, Surgical Forum October 2002 San Francisco, CA
2004	Comparison of antiangiogenic therapy with thrombospondin type I repeats and	Invited Speaker, American College of Surgeons, Surgical Forum October 2004

	gemcitabine in an orthotopic model of pancreatic cancer in SCID mice.	New Orleans, LA
2004	Antiangiogenic therapy using Thrombospondin – 1 in novel animal models of pancreatic cancer	Invited speaker; American College of Surgeons surgical Biology club III, 10/04 Source of compensation: None
2004	Proapoptotic and survival signaling pathways plays a role in Thrombospondin type I repeat mediated apoptosis in human microvascular endothelial cells.	Invited Speaker, American College of Surgeons, Surgical Forum October 2004 New Orleans, LA
2005	Ultrasound Normal Anatomy of the Head and Neck	Invited Instructor American College of Surgeons Annual Meeting, San Francisco, CA
2005	Hands on Teaching, Ultrasound demonstration	Invited Instructor and Course Examiner American College of Surgeons Annual Meeting, San Francisco, CA
2006	Ultrasound Normal Anatomy of the Head and Neck	Invited Instructor American College of Surgeons Annual Meeting, New Orleans, LA
2005	Hands on Teaching, Ultrasound demonstration	Invited Instructor and Course Examiner American College of Surgeons Annual Meeting, New Orleans, LA
2007	Ultrasound Normal Anatomy of the Head and Neck	Invited Instructor American College of Surgeons Annual Meeting, Chicago, IL
2007	Hands on Teaching, Ultrasound demonstration	Invited Instructor and Course Examiner American College of Surgeons Annual Meeting, Chicago, IL
2008	Ultrasound Normal Anatomy of the Head and Neck	Invited Instructor American College of Surgeons Annual Meeting, San Francisco, CA

2008	Hands on Teaching, Ultrasound demonstration	Invited Instructor and Course Examiner American College of Surgeons Annual Meeting, San Francisco, CA
2008 2008	Obstacles to office based ultrasound for head and neck surgeons Thyroid Surgery, More or Less Surgery	Speaker and panelist at the American College of Surgeons, San Francisco, CA Speaker at the Harvard Advances in Cancer Management for the Surgeon Course, Boston, MA
2008	Office Based Ultrasound, Obstacles to Getting Started	Speaker at the Harvard Course on Surgery of the Thyroid and Parathyroid Glands, Boston, MA
2009	Thyroid Incidentalomas: What to do about this epidemic	Speaker at BayState Medical Center, Springfield, MA Source of compensation: Baystate Medical School Speaker's Bureau
2009	Parathyroid Surgery	Speaker at the Harvard Advances in Cancer Management for the Surgeon Course, Boston, MA
2009	Thyroid Surgery, Vocal Cord Paralysis and nerve monitoring	Speaker at the ThyCa National Annual Meeting, Danvers, MA
2009	Frequently asked questions about thyroid surgery	Speaker at the ThyCa National Annual Meeting, Danvers, MA
2009	Ultrasound Normal Anatomy of the Head and Neck	Invited Instructor American College of Surgeons Annual Meeting, Chicago, IL
2009	Hands on Teaching, Ultrasound demonstration	Invited Instructor and Course Examiner American College of Surgeons Annual Meeting, Chicago, IL
2009	Obstacles to office based ultrasound for head and neck surgeons	Speaker and panelist at the American College of Surgeons, Chicago, IL
2010	BRAF and animal models of thyroid cancer	Speaker and panelist at Molecular Markers Workshop at the American Association of Endocrine Surgeons,

2010	Ultrasound Normal Anatomy of the Head and Neck	Pittsburgh, PA Invited Instructor American College of Surgeons Annual Meeting, Washington DC
2010	Hands on Teaching, Ultrasound demonstration	Invited Instructor and Course Examiner American College of Surgeons Annual Meeting, Washington DC
2010	Obstacles to office based ultrasound for head and neck surgeons	Speaker and panelist at the American College of Surgeons, Washington DC
2010	Intraoperative PTH: Pitfalls	Speaker and panelist at the American College of Surgeons, Chicago, IL
2011	BRAF and thyroid cancer	Invited speaker American Thyroid Association, Palm Springs, CA
2011	Ultrasound Normal Anatomy of the Head and Neck	Invited Instructor American College of Surgeons Annual Meeting, San Francisco, CA
2011	Hands on Teaching, Ultrasound demonstration	Invited Instructor and Course Examiner American College of Surgeons Annual Meeting, San Francisco, CA
2011	Obstacles to office based ultrasound for head and neck surgeons	Speaker and panelist at the American College of Surgeons, San Francisco, CA
2012	Use of more active single agent targeted therapies when first line agents fail	Speaker and panelist at Endocrine Society Meeting, Houston, Texas
2013	Ultrasound Normal Anatomy of the Head and Neck	Invited Instructor ACS Exported course to AAES, Chicago, IL
2013	Setting up office based ultrasound	Invited Instructor ACS Exported course to AAES, Chicago, IL
2014	Hands on Station for Laryngeal Ultrasound	Course director, AAES Boston, MA
2014	Use of novel mouse models of aggressive thyroid cancer for preclinical testing	International Thyroid Oncology Group meeting , Boston MA ( Meeting co- director)

# **International Invited Presentations and Courses**

Year Title of Presentation Type of Presentation

2005	Prognostic Factors in Thyroid Cancer "Novel Horizons in Thyroid Cancers"	Millennium Hospital, Ecuador
2009	Novel Techniques in Thyroid Surgery	Speaker at Union Hospital, Wuhan, China
2013	Molecular targeting: lessons learned from the lab	Plenary session Speaker at Oncoplastic Endocrine Surgery Symposium, Seoul National University, Seoul, Korea
2014	Treating aggressive thyroid cancers	Visiting Professor in Surgery, University of Wisconsin
2014	Surgeons Performed Ultrasound: Lessons Learned by Surgeons	Ethicon Lecturer, International Society of Oncoplastic Endocrine Surgery, Busan, Korea
2014	Association of Women Surgeons Visiting Professor	Tulane University, New Orleans

# **Report of Clinical Activities and Innovations**

### Current licensure and Certifications:

intent nechbare a	na confidencia.
1992	Diplomate, National Board of Medical Examiners
1992	License, California Board of Registration
1993	Federal Controlled Substances Registration Certificate
1995	License, Massachusetts Board of Registration
1998/2008	Massachusetts Controlled Substances Registration
1998	Advanced Trauma Life Support Instructor Certificate
1999	Diplomate, American Board of Surgery, Certificate
2003	Recertified in Basic Ultrasound and Head and Neck
	Ultrasound, American College of Surgeons
2004	Certified as Instructor by the National Ultrasound Faculty of the
	American College of Surgeons, for the purpose of teaching
	ultrasound to staff and residents.

# **Current Practice Activities**

Type of Activity	<b>Setting of Practice</b>	Name & Location of Practice	Level of Activity
Endocrine Surgery	Outpatient Clinic	Endocrine Surgery, Wang 460	One session per week
Endocrine Surgery	Outpatient Clinic	Boston Thyroid Center, Longwood Medical Area	One session per week
Endocrine Surgery	Outpatient Clinic	Mt. Auburn Hospital	One session per week
Endocrine Surgery	Operating Room	MGH Operating Room	One session per week Approx 180 endocrine cases last year total
Endocrine Surgery	Operating Room	Mount Auburn Operating Room	One session per week

# **Clinical Innovation**

Date Initiated/ Date Implemented	Title	Scope of project
2000/2002-2005	BIDMC Thyroid Center Co-founded with Dr. Anthony Hollenberg of Endocrinology	BIDMC Thyroid Center, instrumental role in creating a "one stop shopping" model for treatment of the increasingly common "thyroid nodules". Multidisciplinary streamline approach to patient with thyroid nodules rather than disparate care from different medical specialties such as surgery, medicine, endocrinology, pathology and cytology. Lessons learned from this approach yielded innovative tools for curriculum development in other hospital settings where a high concentration of multidisciplinary teaching was
2002/2003	BIDMC Thyroid Center Web site developed and implemented with BIDMC Marketing	employed.  Developed a web site for the Thyroid Center at Beth Israel Deaconess Medical Center, www.bidmc.harvard.edu/thyroidcenter
Updated in 2006		Widely used by endocrine patients at BIDMC for a one stop educational resource
2008/2009	MGH Endocrine Surgery Tissue Bank and Molecular Diagnostics Program	Conceived and built new IRB approved prospective database for MGH Endocrine Surgery Tissue Bank using access database. Implemented as an

MGH hospital wide resource for endocrinologist, surgeons and pathologist interested in used patient tissue for research and molecular diagnostics.

# **Report of Education of Patients and Service to the Community**

Activities

Year(s)	Role	Organization or institution
2006	Instructor Body Works Exhibit	Museum of Science
2009	Instructor in metabolic bone disease	Beaver Country Day School

Educational Material for Patients and the Lay Community:

Patient educational material:

<b>Developed and published</b>	<u>Title</u>
2003-2004	"Thyroid Surgery at Beth Israel Deaconess: Information for patients and families" Prepared for and produced and distributed by the Beth Israel Deaconess Learning Center
2003-2004	"Thyroid Surgery: Discharge Instructions" Prepared for and produced and distributed by the Beth Israel Deaconess Learning Center
2005	"Thyroid disease is More Prevalent Among Women, Thyroid nodules and Thyroiditis" Prepared for Women's Health News, Published by Beth Israel Deaconess Medical Center
2009	"Papillary thyroid cancer" section for patient education of the American Association of Endocrine Surgeons Website Report of Scholarship
2012	Frequently asked Questions for the American Association of Endocrine Surgeons Website

# Report of Scholarship

**Publications** 

Peer reviewed Publications:

Research Investigations:

- 1. Shea C., Glass D.J., **Parangi S**. and Van der Ploeg L.H.T. Variant Surface Glycoprotein gene expression site switches in Trypanosoma brucei. J. Biologic Chemistry, 1986; 261(Pt 13): 6056-6063.
- Wong S.M.E, Lindeman R.P., Parangi S. and Chase H.S. Role of calcium in mediating Carbachol's action in T84 cell. Am. J. of Physiology, November 1990; 257: C976-C985.
- 3. Oz M.C., Chuck R.S., Johnson J.P., **Parangi S.**, Bass, L.S., Nowygrod R., and Treat M.R. Indocyanine green dye-enhanced welding with a diode laser Surgical Forum XL, October 1989: 317-318.
- 4. Oz M.C., Johnson J.P, **Parangi S.**, Chuck R.S. and Treat M.R. Tissue soldering by use of Indocyanine green dye enhanced fibrinogen with the near infrared diode laser. J. of Vascular Surgery, May 1990; 11: 718-725.
- 5. Oz M.C., Chuck R.S., Johnson J.P, **Parangi S**., Nowygrod R. and Treat M.R. Indocyanine green dye enhanced vascular welding with the near infrared diode laser Vascular Surgery, October 1990; 24: 564-570.
- Oz M.C., Johnson J.P, Parangi S., Chuck R.S. and Treat M.R. Strength of laser vascular fusion- preliminary observations on the role of thrombus Lasers in Surgery and Medicine, 1990; 10: 393-395.
- 7. **Parangi S.,** Radany E.R., Christofori, G., Dietrich, W., Lander E.S., Folkman J., and Hanahan D. Chromosomal deletions in early stages of tumor progression: Search for a novel tumor suppressor or angiogenesis suppressor gene. Surgical Forum XLV, October 1994: 505-506.
- 8. Chen C., **Parangi S**., Tolentino M.J. and Folkman J. A strategy to discover circulating angiogenesis inhibitors generated by human tumors Cancer Research October 1995; 55: 4230-4233.
- 9. Klauber N., **Parangi, S**., Hamel E., and D'Amato R.J. Growth suppression of a human breast carcinoma in vivo and inhibition of angiogenesis in vivo by the endogenous estrogen metabolite 2-methoxyestradiol Surgical Forum XLVI, October 1995: 470-472.
- 10. **Parangi S.**, Dietrich W., Christofori G., Lander E.S., and Hanahan D.Tumor suppressor loci on mouse chromosomes 9 and 16 are lost at distinct stages of tumorigenesis in a transgenic model of islet cell carcinoma Cancer Research, December 15 1995; 55: 6071-6076.
- 11. **Parangi S.**, O'Reilly M.O., Christofori G., Holmgren L., Grosfeld J., Folkman J., and Hanahan D. Antiangiogenic therapy of transgenic mice impairs de novo tumor growth Proc. Natl. Acad. Sci March 1996; 93: 2002-2007.
- 12. Klauber N., **Parangi S.,** Flynn E., Hamel E., and D'Amato R.J. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2 Methoxyestradiol and Taxol Cancer Research January 1997; 57: 81-86.
- 13. Arbiser J., Moses M.A., Fernandez, C., Ghiso N., Cao, Y., Klauber N., Frank, D., Brownlee M., Flynn E., **Parangi S.**, Byers R. and Folkman J. Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathway Proc. Natl.Acad.Sci February 1997; 94: 861-866.
- 14. Evans C.P., Elfman F., **Parangi S**., Conn M., Cunha G., Shuman M.A., Inhibition of prostate cancer neovascularization and growth by urokinase plasminogen activator receptor blockade Cancer Research August 1997; 57: 3594-3599.

- 15. **Parangi S.**, Matthews, J.B., Delic, M., Duquette, M., and Lawler, J Antiangiogenic therapy with thrombospondin reduces tumor volume in an orthotopic model of pancreatic cancer in SCID mice Surgical Forum October 1999 Volume L.: 87-88
- 16. **Parangi S.**, Delic M., Lawler J., and Terwilliger E., "Gene therapy with a recombinant adenoassociated virus (rAAV) in an orthotopic model of pancreatic cancer in SCID mice" <u>Surgical Forum</u> October 2001 Volume: 131-132
- 17. Zeng H, Datta K, Neid M, Li J, **Parangi S**, and Mukhopadhyay D.; "Requirement of different signaling pathways mediated by insulin-like growth factor-I receptor for proliferation, invasion, and VPF/VEGF expression in a pancreatic carcinoma cell line" Biochem Biophys Res Commun. 2003 Feb 28; 302(1):46-55
- 18. Mitchell J. and **Parangi, S**; "Laparoscopic adrenalectomy for pheochromocytoma" Current Surgery. November 2003; 60: 561-566
- 19. Stephan, S., Datta, K., Wang, E., Li, J. Brekken, R.A., **Parangi, S,** Philip E. Thorpe, P.E. and. Mukhopadhyay, D.; Effect of Rapamycin Alone and in Combination with Anti-Angiogenesis Therapy in an Orthotopic Model of Human Pancreatic Cancer. Clinical Cancer Res. October 15;10 (20):6993-7000. 2004
- 20. Mitchell J. and **Parangi, S**; "Angiogenesis in Benign and Malignant Thyroid Disease", Mitchell J. and **Parangi, S**; "Angiogenesis in Benign and Malignant Thyroid Disease", Thyroid, Volume 15 (6) 494-510, June 2005
- 21. Zhang XF, Galardi E Duquette M, Delic, M Lawler J, and **Parangi, S**: "Antiangiogneic treatment with Thrombospondin-1 Three type I repeat recombinant proteins in an Orthotopic Human Pancreatic Cancer model" Clinical Cancer Research, Mar 15; 11(6):2337-44; 2005
- 22. Ren B., Wang Y., Ndebele K., Chen F., Wang, Y., and **Parangi S** "Multiple signaling is involved in endostatin-mediated apoptosis in ECV 304 endothelial cells "Frontiers in Bioscience, May 1:10:1089-97; 2005
- 23. Zhang XF, Galardi E Duquette M, Lawler J, and **Parangi, S**: "Antiangiogenic Treatment with Three Thrombospondin-1 Type 1 Repeats versus Gemcitabine in an Orthotopic Human Pancreatic Cancer Model" Clinical Cancer Research, 11(15) 5622-5630, August 2005,
- 24. Mitchell J.C Grant F.D.; Evenson A.R.; Parker J. A., Hasselgren PO; and **Parangi,** S.: "Pre-Operative Evaluation of Thyroid Nodules with <sup>18</sup>FDG-PET/CT". Surgery, 138(6), 1166-1176, December 2005
- 25. Upalakalin J. N., Collins L. C, , Tawa N, and **Parangi S**: Carcinoid Tumors in the Breast , American Journal of Surgery, Am J Surg. 2006 Jun;191(6):799-805.
- 26. Zhang XF, Connolly C, Duquette M, Lawler J, and **Parangi, S**: "Continuous Administration of the Three Thrombospondin-1 Type 1 Repeats Recombinant Protein Improves the Potency of Therapy in an Orthotropic Human Pancreatic Cancer Model". Cancer Letters, 2006 June 4
- 27. Evenson A., Mitchell J, Wei W, Poylin V, **Parangi S**, and Hasselgren P.O: "The gene expression and activity of calpains and the muscle wasting-associated ubiquitin ligases, atrogin-1 and MuRF1, are not altered in patients with primary hyperparathyroidism." Int J Mol Med. 2006 Sep; 18 (3):471-5
- 28. Zhang, XF, Xu J, Lawler J, Terwilliger E and **Parangi S**: Adeno-Associated Virus-Mediated Antiangiogenic Gene Therapy with Thrombospondin-1 Type 1 Repeats and Endostatin." Clinical Cancer Research 2007 Jul 1; 13(13):3968-76

- 29. Zhang, XF and **Parangi, S** "Quantification of vascular endothelial cell apoptosis in vivo." Methods Enzymol. 2008;446:287-92
- 30. Demirjian AN, Grossman JM, Chan JL and **Parangi S**.: "Parathyroid carcinoma and neurofibromatosis." Surgery 2008; 827-829
- 31. Nucera C, Goldfarb M, Hodin R and **Parangi S**.: "Role of B-Raf<sup>V600E</sup> in differentiated thyroid cancer and preclinical validation of compounds against B-Raf<sup>V600E</sup>". BBA Reviews on Cancer, 2009 Apr; 1795(2):152-61.
- 32. Zhang X, Kazerounian S, Duquette M, Perruzzi C, Nagy JA, Dvorak HF, **Parangi** S, and Lawler J.:Thrombospondin-1 Modulates VEGF Activity at the Receptor Level, FASEB Journal, June 15 2009
- 33. Ren B, Song K, **Parangi S**, Jin T, Ye M, Humphreys R, Duquette M, Zhang X, Benhaga N, Lawler J, Khosravi-Far R: A double hit to kill tumor and endothelial cells by TRAIL and Antiangiogenic 3 TSR: Cancer Res. 2009 May 1;69(9):3856-65.
- 34. Oneal P, Poylin, V, Mowschenson P, **Parangi S**, Horowitz G and Hasselgren PO: When initial post excision PTH levels do not fall during parathyroidectomy: What to do next, World Journal of Surgery, May 4 2009
- 35. Mekel M, , Stephen A. E., Gaz R. D., Hodin R. A., and **Parangi S**: "Thyroid surgery in octogenarians is associated with higher complication rates." Surgery, Surgery. 2009 Jul 10.
- 36. Mekel M, Stephen AE, Gaz, RD, Randolph GW, Lubitz CC, Nehs MA, **Parangi** S, and Hodin RA. "Surgical drains can be safely avoided in modified radical neck dissections for thyroid cancer", American Journal of Surgery, 2010 199(4):485-90
- 37. Nucera C, Nehs MC, Mekel M, Zhang X, Hodin R, Lawler J, Nose V, and **Parangi, S**: A novel orthotopic mouse model of human anaplastic thyroid carcinoma. Thyroid. 2009 Oct;19(10):1077-84.
- 38. Lubitz CC, Faquin WC, Yang J, Hodin RA, Gaz RD, **Parangi S,** Randolph G and Stephen AE "Clinical and Cytological Features Predicitve of Malignancy in Follicular Neoplasms" Thyroid. 2010 Jan;20(1):25-31.
- 39. Nucera C, Porello, A, Antonello ZE, Mekel M Nehs MC, Giordano TJ, Gerald D, Bejamin LE, Priolog C, Puxeddu E, Finn S, Jarzab B, Hodin RA, Pontercorvi A, Nose V, Lawler J, and **Parangi, S**:B-Raf<sup>V600E</sup> and Thrombospondin-1 Promote Thyroid Cancer Progression. Proc Natl Acad Sci U S A. 2010 Jun 8;107(23):10649-54. Epub 2010 May 24.
- 40. Mekel M, Nucera C, Hodin RA, and **Parangi S:** Surgical Implications of BRAF V600E mutation in fine needle aspiration of thyroid nodules., Am J Surg. 2010 Jul;200(1):
- 41. Nehs MC, Nagarkatti, S, Nucera C, Hodin RA, and **Parangi, S**: "Thyroidectomy with neoadjuvant PLX4720 extends survival and decreases tumor burden in an orthotopic mouse model of anaplastic thyroid cancer." Surgery. 2010 Dec;148(6):1154-62; discussion 1162.
- 42. Godlfarb M, Gondek S, Hodin RA, and **Parangi S**.: Resident/Fellow assistance in the operating roomfor endocrine surgery in the era of fellowships." Surgery. 2010 Dec;148(6):1065-71; discussion 1071-2.
- 43. Lubitz CC, Hunter GJ, Hamberg, LM, **Parangi S,** Ruan D, Gwande, A, Gaz RD, Randolph GW, Moore FD, Hodin RA, and Stephen AE: Accuracy of 4D-CT in

- Poorly-Localized Patients with Primary Hyperparathyroidism, Surgery. 2010 Dec;148(6):1129-37; discussion 1137-8.
- 44. Yip L, Kebebew E, Milas M, Carty SE, Fahey TJ, **Parangi S**, Zeiger MA, and Nikiforov YE: Summary statement: Utility of molecular marker testing in thyroid cancer. Surgery Dec, 2010 148(6): 1313-5
- 45. Nucera C, Lawler J, and **Parangi**, S: BRAF<sup>V600E</sup> and microenvironment in thyroid cancer: a functional link to drive cancer progression. Cancer research in press
- 46. Nucera C, Lawler J, Hodin RA, and **Parangi, S** The BRAF<sup>V600E</sup> mutation: what is it really orchestrating in thyroid cancer? Oncotarget, 2010 Dec;1(8):751-6.
- 47. Nucera C, Nehs MA, Nagarkatti SS, Sadow PM, Mekel M, Fischer AH, Lin PS, Bollag GE, Lawler J, Hodin RA, and **Parangi S**.: Targeting BRAF<sup>V600E</sup> with PLX4720 displays potent anti migratory and invasive activity in preclinical models of human thyroid cancer, Oncologist. 2011 Feb 25.
- 48. Godlfarb M, Perry Z, Hodin RA, and **Parangi S:** Medical and surgical risks in thyroid surgery: Lessons from the NSQIP. Ann Surg Oncol. 2011 Dec;18(13):3551-8. Epub 2011 Jul 20.
- 49. Yip DT, Hassan M, Pazaitou-Panayiotou K, Ruan DT, Gawande AA, Gaz RD, Moore FD Jr, Hodin RA, Stephen AE, Sadow PM, Daniels GH, Randolph GW, Parangi S, Lubitz CC: Preoperative basal calcitonin and tumor stage correlate with postoperative calcitonin normalization in patients undergoing initial surgical management of medullary thyroid carcinoma. Surgery. 2011 Dec;150(6):1168-77. doi: 10.1016/j.surg.2011.09.043.PMID:22136837
- 50. Nehs MA, Nucera C, , Nagarkatti SS, Sadow PM, Morales-Garcia D, Hodin RA, and **Parangi S**.: Late intervention with anti BRAF<sup>V600E</sup> therapy induces regression in an orthotopic mouse model of human anaplastic thyroid cancer. Endocrinology. 2012 Feb;153(2):985-94. Epub 2011 Dec 27.PMID: 22202162 [PubMed in process]
- 51. Barbesino G, Godlfarb M, **Parangi** S, Yang J, Ross D, and Daniels G: Lobe ablation with radioactive iodine as an alternative to completion thyroidectomy after hemithyroidectomy in patients with follicular thyroid cancer: long-term follow-up. Thyroid. 2012 Mar 2. [Epub ahead of print] PMID: 22385290
- 52. Samir AE, Vij A, Seale MK, Desai G, Halpern E, Faquin WC, **Parangi S**, Hahn PF, and Daniels GH: Ultrasound-guided percutaneous thyroid nodule core biopsy: Clinical Utility in patients with prior non diagnostic fine needle aspirate. Thyroid. 2012 Feb 3. PMID: 22304390
- 53. Lubitz CC, Nagarkatti SS, Faquin WC, Samir AE, Hassan MC, Barbesino G, Ross DS, Randolph GW, Gaz RD, Stephen AE, Hodin RA, Daniels GH, and **Parangi S:** Diagnostic Yield of Non-Diagnostic Thyroid Nodules Is Not Altered by Timing of Repeat Biopsy. Thyroid. 2012 Jun;22(6):590-4..PMID: 22667452
- 54. Nagarkatti SS, Faquin WC, Lubitz CC, Morales-Garcia D, Barbesino G, Ross DS, Hodin RA, Daniels GH, and **Parangi S:** The management of Thyroid Nodules with Atypical Cytology on Fine Needle Aspiration. Ann Surg Oncol. 2013 Jan;20(1):60-5. PMID: 22941160
- 55. Prescott JD, Sadow PM, Hodin RA, Le LP, Gaz RD, Randolph GW, Stephen AE, **Parangi** S, Daniels GH, and Lubitz CC.: BRAF(V600E) status adds incremental

- value to current risk classification systems in predicting papillary thyroid carcinoma recurrence. Surgery. 2012 Dec;152(6):984-90. PMID: 23158172
- 56. Qin L, Zhao D, Xu J, Ren X, Terwilliger EF, **Parangi S**, Lawler J, Dvorak and HF, Zeng H. The vascular permeabilizing factors histamine and serotonin induce angiogenesis through TR3/Nur77 and subsequently truncate it through thrombospondin-1. Blood. 2013 Mar 14;121(11):2154-64. PMID: 23315169
- 57. Phitayakorn R, Morales-Garcia D, Wanderer J, Lubitz CC, Gaz RD, Stephen AE, Ehrenfeld JM, Daniels GH, Hodin RA, **Parangi** S Surgery for Graves' disease: a 25-year perspective. Am J Surg. 2013 Nov;206(5):669-73. Epub 2013 Sep 4.PMID:24011567
- 58. Gunda, V, Cogdill, AP, Bernasconi, MJ, Wargo, JA and **Parangi, S:** Potential role of 5- aza-2'-deoxycytidine induced MAGE-A4 expression in immunotherapy for anaplastic thyroid cancer. Surgery. 2013 Dec;154(6):1456-62; discussion 1462. PMID:24238058
- 59. Vanden Borre P, McFadden DG, Gunda V, Sadow PM, Varmeh S, Bernasconi MJ, Jacks T, **Parangi S**: The Next Generation of Orthotopic Thyroid Cancer Models: Immunocompetent Orthotopic Mouse Models of BRAF<sup>V600E</sup>-Positive Papillary and Anaplastic Thyroid Carcinoma. Thyroid. 2013 Dec 2.PMID:24295207
- 60. Gunda V, Bucur O, Varnau J, Vandenborre, Bernasconi MJ, Khosravi-far R, and **Parangi S:** Blocks to thyroid cancer cell apoptosis can be overcome by inhibition of the MAPK and PI3K/AKT Pathways Cell death and disease Cell Death Dis. 2014 Mar 6;PMID: 24603332
- 61. Gunda V, Frederick DT, Bernasconi MJ, Wargo JA, and **Parangi S.** A potential role for immunotherapy in thyroid cancer by enhancing NY-ESO-1 cancer antigen expression. Thyroid. 2014 May 8.PMID:24811699
- 62. Bernet V, Hupart KH, **Parangi** S, Woeber KA. AACE/ACE Disease State Commentary: Molecular Diagnostic Testing of Thyroid Nodules with Indeterminate Cytopathology. Endocr Pract. 2014 Apr 1;20(4):360-3.PMID:24727662
- 63. **Parangi S,** Suh H The Role of Genetic Markers in the Evaluation and Management of Thyroid Nodules. Surg Clin North Am. 2014 Jun;94(3):515-528.. Epub 2014 Apr 24.PMID:24857574
- 64. Vanden Borre P, Gunda V, McFadden DG, Sadow PM, Varmeh S, Bernasconi MJ, **Parangi S:** Combined BRAF<sup>V600E-</sup> and SRC-inhibition induces apoptosis, evokes an immune response and reduces tumor growth in an immunocompetent orthotopic mouse model of anaplastic thyroid cancer. Oncotarget, Accepted for publication June 2014

# Peer reviewed publications (Meta-analysis, meeting proceedings with full manuscript, case reports etc..

 Tyrell D., Parangi S., Gantert W., Fugino Y., Way L.W., Duh Q.Y. Laparoscopic Janeway Gastrostomy SAGES Meeting, <u>SAGES Educational Video Library</u> 1997 98L.

- 2. **Parangi S.**, Oz M.C., Blume R.S., Bixon R. and Nowygrod R. Hepatobiliary complications of Polyarteritis Nodosa, Archives of Surgery, July 1991; 126: 909-912
- 3. D'Avanzo A., **Parangi S.**, Morita E., Duh Q.Y., Siperstein A.E., and Clark O.H. Hyperparathyroidism after thyroid surgery and autotransplantation of histologically normal parathyroid glands <u>J. Amer. College of Surgeons</u> May 2000; 190 (Pt 5): 546-52.
- 4. D'Avanza A., **Parangi S.**, Morita E, Perrier N, Wu H, Siperstein A, Duh Q, Tressler P, and Clark OH; "False Positive 99mTc Sestamibi Scans in Patients with Osteitis Fibrosa Cystica and Brown Tumours" Eur. J. Surg 2001 167: 592-597
- 5. Saurborn D.P., Kruskal J.B., Stillman, I.E., and **Parangi, S**; "Best cases from the AFIP:Paranganglioma of the Organs of Zuckerkandl" Radiographics. 2003; Sep-Oct; 2003(5): 1279-1286
- 6. Gremmels, J.M., Kruskal, J.B., **Parangi, S** and Kane, R.A.; "Hemorrhagic Cholecystitis Simulating Gallbladder Carcinoma" Journal of Ultrasound in Medicine, 2004 Jul; 23(7):993-51.
- 7. Silver, R. J. and **Parangi,S**; "Management of Thyroid Incidentalomas" Surgical Clinics of North America. 2004 Jun; 84(3):907-19
- 8. Mitchell J. and **Parangi,S** "Thyroid Incidentalomas: A New Epidemic," Current Surgery. November 2004; Volume 61(6), 545-51.
- 9. Mitchell J. and **Parangi, S**; "The Thyroid Incidentaloma: An Increasingly Frequent Consequence of Radiologic Imaging", Seminars in Ultrasound, CT and MRI, Feb;26(1):37-46; 2005
- 10. Kim, Min P, Vin, Yael and **Parangi, S**: Image of the month "Gallstone Ileus" Archives of Surgery, 2005
- 11. Warren, AG. and **Parangi**, **S**: Image of the month "Acute and Chronic Cholecystitis". Archives of Surgery, January 2006
- 12. Osborn, C and **Parangi, S**: "Partial Thyroidectomy: Illustrated Reflections for Surgical Residents" Current Surgery, Jan-Feb; 63(1):39-43, 2006
- 13. **Parangi S**., Levine D., Henry A, Isakovich N, and Pories S: "Surgical gastrointestinal disorders during pregnancy" American Journal of Surgery, 2007 Feb; 193(2):223-32
- 14. Evenson AR, Mowschenson PM, **Parangi S**, and Hasselgren PO: "Hyalinizing trabecular adenoma an uncommon thyroid tumor frequently misdiagnosed as papillary or medullary thyroid carcinoma" The American Journal of Surgery, Am J Surg. 2007 Jun; 193(6):707-12.
- 15. Lubitz CC, Faquin WC, Gaz R, **Parangi S**, Randolph GW, Hodin RA, Stephen AE. Metastatic Melanoma to Thyroid: A Case Report and Institutional Reveiw. World Journal of Endocrine Surgery. 2010 May-Aug; 2 (2): 97-100.
- 16. Cabot RC, Harris NL, Shepard JA, Rosenberg ES, Cort AM, Peters CC, Misra M, Parangi S, Ross DS, Shailam R and Sadow PM: Case records of the Massachusetts General Hospital: Case 38-2010: A 13 year old girl with an enlarging neck mass, NEJM CPC: December 2010 In press N Engl J Med. 2010 Dec 16;363(25):2445-54

#### Non-peer reviewed scientific or medical publications

#### Reviews, Book chapters, Monographs, Editorials

- 1. **Parangi S.,** Hodin R. "Laparoscopic appendectomy". In: Bland, K, editor. The Practice of General Surgery. W.B. Saunders, 2000,
- 2. **Parangi S.,** Hodin R. "Abdominal Cavity: Anatomy, Structural Anomalies and Hernias". In Yamada,T, Editor "Textbook of Gastroenterology" 4<sup>th</sup> edition, Lippincott Williams &Wilkins, 2001.
- 3. **Parangi S.,** Hodin R. "Abdominal Cavity: Anatomy, Structural Anomalies and Hernias". In Yamada, T, Editor "Atlas of Gastroenterology" 4<sup>th</sup> edition, Lippincott Williams & Wilkins, 2001
- **4. Parangi S.** and Pories, S. "Surgical Problems in the Pregnant Patient" in Monograph titled: Gastrointestinal Disorders during Pregnancy, Published by the American College of Gastroenterology, 2003
- 5. **Parangi S.** and Hodin R. Chapter 58: "Intestinal Obstruction", Published in Therapy of Gastrointestinal Disorders, Second edition, 2004
- 6. Mitchell J., Hollenberg A., and **Parangi, S**; "The Role of the Endothelium in Normal and Pathologic Thyroid Function" Chapter published in Endothelial Biomedicine, 2006,
- 7. **Parangi, S**; and Lawler, J: The Thrombospondins", Chapter published in Endothelial Biomedicine, 2006,
- 8. **Parangi S**. "Thyroid " "Pineal Gland" and "Hashimoto's" in World Book Encyclopedia 2007 and 2008
- 9. Mekel M, and **Parangi S**. "Endocrine surgery" and "Head and Neck" chapter published in Oxford American Handbook of Surgery, edited by David Berger, Oxford University Press, New York, 2009.
- 10. Nucera, C, Parker J.A., and **Parangi S**. "Thyroid Imaging" Chapter published in Endocrine Surgery (Springer Specialist Surgery Series) Edited by Johnathan G H Hubbard, William B. Inabnet, and Chung-Yau Lo 2009
- 11. **Parangi, S**: "Thyroid Nodules" and "Hyperthyroidism" Modules for the American Board of Surgery educational project of the Surgical Council on Resident Education (SCORE) 2009

- 12. Perrier ND and **Parangi S** "Minimally invasive single gland parathyroid exploration" published in Surgery of the Thyroid and Parathyroid Glands, Second edition, 2013
- 13. McKenzie, T and **Parangi, S** "Prophylactic Central node dissection for papillary thyroid carcinoma" for Clark: Textbook of Endocrine Surgery, third edition 2013

#### Books

1. Phitayakorn and **Parangi, S** Book "Thyroid Disease" in series Biography of Diseases. Published by ABC-Clio 2010

#### Professional Educational Materials or Reports, in print or other media

Print Material:

1. BIDMC Surgical Residency Core Curriculum in Endocrine Surgery Syllabus Syllabus of Educational Material and Case presentations for the BIDMC Surgical Residency Core Curriculum in Endocrine Surgery, Thyroid Neoplasms, Parathyroid Disorders and Adrenal masses

#### Non Print Material:

2002	Developed a web site for the Thyroid Center at Beth Israel
	Deaconess Medical Center, <a href="www.bidmc.harvard.edu/thyroidcenter">www.bidmc.harvard.edu/thyroidcenter</a> .
2005	Updated and revised new web site for BIDMC Thyroid Center
2009	Conceived and revised new database for MGH Endocrine Surgery
	Tissue Bank
2012	Frequently asked questions section for the American Association
	of Endocrine Sections website and Sharecare

#### Abstracts (since 2005):

- 1. Grant F.D., Mitchell J.C.; Evenson A.R.; Parker J. A., Hasselgren PO; and **Parangi, S.**: Pre-Operative Evaluation of Thyroid Nodules with. *American Association of Endocrine Surgeons April, 2005, Cancun, Mexico*
- 2. Zhang XF,Galardi E Duquette M Lawler J, and **Parangi, S:** Comparison of thrombospondin type I repeats antiangiogenic therapy with gemcitabine in an orthotopic pancreatic cancer model. Poster at the American Association of Cancer Research April, 2005, Anaheim, CA
- 3. Grant F.D., Mitchell J.C.; Evenson A.R.; Parker J. A., Hasselgren PO; and **Parangi, S.**: Pre-Operative Evaluation of Thyroid Nodules and identification of thyroid cancer by <sup>18</sup>FDG-PET/CT.Society of Nuclear Medicine, 52<sup>nd</sup> Annual Meeting, May 2005

- 4. Evenson, A, Mitchell, J.C, Wei, W, Poylin, V, **Parangi, S**; and Hasselgren P.O.: The Gene expression of Calpains and the Muscle Wasting –Associated Ubiquitin Ligases Atrogin-1 and Murf-1 is not Altered in Patients with Primary Hyperparathyrodisim. Oral Presentation at the 52<sup>nd</sup> Annual Meeting of The Massachusetts Chapter of the American College of Surgeons, 11/19/2005
- 5. Mitchell, J.C, Grant F, Evenson, A, Parker, A, Hasselgren P.O. and **Parangi, S**: The Utility of Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in the Pre-operative Evaluation of Thyroid Nodules. 52<sup>nd</sup> Annual Poster Presentation at Meeting of The Massachusetts Chapter of the American College of Surgeons, 11/19/2005
- 6. Zhang, X.F. Connolly C, Duquette, M Lawler J, and **Parangi, S.**:Continuous Administration of the Three Thrombospondin-1 Type 1 Repeats Recombinant Protein Improves the Potency of Therapy in an Orthotopic Human Pancreatic Cancer Model. Antiangiogenesis and Drug Delivery to Tumors, Bench to Bedside AACR Meeting November 2005, Boston
- 7. Xuefeng Zhang, Jianfeng Xu, Jack Lawler, Ernest Terwilliger, and **Sareh Parangi** "Adeno-Associated Virus-Mediated Anti-Angiogenic Gene Therapy
  with Thrombospondin-1 Type 1 Repeats and Endostatin" February 2007, Center
  for Vascular Biology Annual Retreat, Podium talk, winner of postdoctoral fellow
  presentation award.
- 8.Mekel M, MD, Stephen A. E. MD, Gaz R. D. MD, Hodin R. A. MD, and **Parangi S,** MD: "Thyroid surgery in octogenarians is associated with higher complication rates." Podium Talk American Thyroid Association, Chicago September 2008
- 9. Nucera C, Porrello A, Zhang X, Giordano T, Jarzab B, Trimarchi F, Pontecorvi A, Nose' V, Lawler J, and **Parangi S**: "Identification of new BRAF<sup>V600E</sup> activated pathways by Gene Set Enrichment Analysis (GSEA) of human papillary thyroid cancers (PTCs) gene microarray platform" Podium Talk American Thyroid Association, Chicago September 2008
- 10. Goldfarb M and Parangi S: "Prevalence of neck and back injury in endocrine surgeons". New England Surgical Society, Boston, MA September 2008
- 11. Nucera C, Porrello A, Antonello, Z Zhang X, Giordano T, Jarzab B, Trimarchi F, Pontecorvi A, Nose' V, Lawler J, and **Parangi S**: "Thrombospondin-1 is modulated by the B-Raf<sup>V600E</sup> pathway in papillary thyroid cancer" Abstract US and Canadian Academy of Pathology Meeting, March 2009, Boston
- 12. Zhang X, **Parangi S** and Lawler J: "Regulation of VEGF-induced vascular permeability and VEGFR2 signaling by thrombospondin-1". Abstract US and Canadian Academy of Pathology Meeting, March 2009, Boston

- 13. Lubitz CC, Faquin WC, Yang J, Hodin RA, Gaz RD, **Parangi S,** Randolph G and Stephen AE "Clinical and Cytological Features Predicitve of Malignancy in Follicular Neoplasms" Poster Competitions for the American Association of Endocrine Surgeons May 2009, Madison, WI
- 14. Nehs M, Mekel M, Pontecorvi A, Nose' V, Lawler J Hodin RA., and **Parangi S** "Inhibition of B-Raf<sup>V600E</sup> oncoprotein prevents cell cycle progression, tumor growth and invasion of thyroid cancer cells in vitro and in an orthotopic model of thyroid cancer." Winner of the basic science Poster Competitions for the American Association of Endocrine Surgeons May 2009, Madison, WI
- 15. Mekel M, Stephen AE, Gaz, RD, Randolph GW, Lubitz CC, Nehs MA, **Parangi S**, Hodin RA. "Surgical drains can be safely avoided in modified radical neck dissections for thyroid cancer" Poster Presentation at the American Association of Endocrine Surgeons May 2009, Madison, WI
- 16. Goldfarb M, Mekel M, Hodin RA and **Parangi S:** Comparing perioperative surgical outcomes in patients undergoing thyroid surgery for benign or malignant diseases using the American College of Surgeons National Surgical Quality Improvement Program (NSQIP). Podium presentation at the World Congress on Thyroid Cancer, Toronto August 2009
- 17. Nucera C, Porrello A, Antonello, Mekel M, Nehs M Giordano T, Priolo C, Gerald D, J Efisio Puxeddu, Pontecorvi A, Nose' V, Lawler J, and **Parangi S**: A Robust B-Raf<sup>V600E</sup> Genome-Wide Signature in Papillary Thyroid Cancer. Podium Talk American Thyroid Association, West Palm Beach September 2009.
- 18. Michal Mekel, Goldfarb M, Perry Z, Hutter M, Hodin RA, and **Parangi S:** Body Mass Index and Thyroid Cancer Risk. Poster Presentation American Thyroid Association, West Palm Beach September 2009.
- 19. Nagarkatti SS, Faquin WC, Mekel M, Perry Z, Hodin RA, Barbesino G, Ross DS, Daniels GH, and **Parangi S**: The management of thyroid nodules with atypical cytology on fine needle aspiration biopsy. Poster Presentation American Thyroid Association, West Palm Beach September 2009
- 20. Barbesino G, Goldfarb, **Parangi S,** Yang, J, Ross DS, and Daniels GH.Remnant Lobe Ablation with I 131 is an effective alternative in follicular thyroid cancer: Long term follow up of 39 cases. Poster Presentation American Thyroid Association, West Palm Beach September 2009
- 21. Nagarkatti SS, Lubitz CC, Korngold E, Samir A, Arellano H, Yang J, Gaz RG, **Parangi S**, Randolph GW, Hodin RA, and Stephen AE: Doppler flow in thyroid follicular neoplasms: is it useful? Poster Presentation American Thyroid Association, West Palm Beach September 2009

- 22. Nehs MA, Nagarkatti S, Nucera C, Hodin RA, and **Parangi S:** Thyroidectomy with neoadjuvant PLX4720 extends survival and decreases tumor burden in an orthotopic mouse model of anaplastic thyroid cancer. Winner of the best basic science resident research oral presentation award at the American Association of Endocrine Surgeons, Pittsburgh, PA in April 2010.
- 23. Nehs MA, Nucera C, Nagarkatti S, Hodin RA, and **Parangi S:** Dacarbazine inhibits cell cycle progression and reduces tumor growth in an orthotopic model of anaplastic thyroid cancer. Abstract poster at the American Association of Endocrine Surgeons, Pittsburgh, PA April 2010.
- 24. Goldfarb M, Gondek S, Hodin RA and **Parangi S:** Resident / Fellow Assistance in the Operating Room for Endocrine Surgery in the Era of Fellowships. Podium presentation at the American Association of Endocrine Surgeons, Pittsburgh, PA April 2010
- 25. Lubitz CC, Hunter GJ, Hamberg LM., **Parangi S**, Ruan D, , Gawande A, Gaz RD, Randolph GW,. Moore FD, Jr., Hodin RA, and. Stephen AE: Accuracy of 4D-CT in Poorly-Localized Patients with Primary Hyperparathyroidism. Podium presentation at the American Association of Endocrine Surgeons, Pittsburgh, PA April 2010
- 26. Phitayakorn R, Hodin RA, **Parangi S**, Sagnwaiya MJ, and Stephen A: Do patients with incidentally discovered adrenal masses get the recommended biochemical testing and follow up? Abstract poster at the American Association of Endocrine Surgeons, Pittsburgh, PA April 2010.
- 27. Nucera C, Porrello A, Nehs M, Nehs M Giordano T, Puxeddu E, Jarzab B, Pontecorvi A, Nose' V, Hodin RA, Lawler J, and **Parangi S**: A novel for for B-Raf<sup>V600E</sup> in Thyroid Cancer Progression: from a robust Genome-Wide Analysis to an orthotopic mouse model. Oral Highlight in plenary session on thyroid cancer, Italian Endocrinology Meeting (GEP) June 12, 2010 Pisa, Italy.
- 28. Nehs MA, Nagarkatti S, Nucera C, Sadow, PM, Hodin RA, and **Parangi S:** PLX4720 reverses cachexia, induces regression and extends survival in a mouse model of late stage anaplastic thyroid cancer. Podium presentation and winner of the best resident paper, American College of Surgeons, October 2010
- 29. Nucera C, Nehs MA, Nagarkatti S, Sadow, PM, Mekel MM, Fischer AH, Lawler J, Hodin RA, and **Parangi S**: PLX4720 inhibits cell proliferation and migration/invasion in human thyroid cancer cells, and inhibits tumor growth and metastasis in an orthotopic mouse model of anaplastic thyroid cancer harboring B-Raf<sup>V600E</sup>. American Thyroid Association International Thyroid Congress, Paris September 2010. Winner of the best basic science presentation.

- 30. Nehs MA, Nagarkatti S, Nucera C, Sadow, PM, Hodin RA, and **Parangi S:** PLX4720 reverses cachexia and induces regression of anaplastic thyroid cancer. Podium presentation and winner of the best resident paper, Massachusetts Chapter of the American College of Surgeons, December 2010
- 31. Yip D, Hassan M, Ruan D, Gawande A, Gaz RD, Moore FD, Hodin RA, Stephen AE, Daniels G, Randolph GW, **Parangi S**, and Lubitz C: Preoperative basal calcitonin level and not extent of surgery predicts postoperative calcitonin levels in patients undergoing initial surgical management of medullary thyroid carcinoma. Oral presentation at the American Association of Endocrine Surgeons April 2011, Houston TX
- 32. Phitayakorn R, **Parangi S**, Hodin RA, Sofferman RA,Randolph G, and Stephen AE: Ultrasound Use by Endocrine Surgeons. Poster presentation at the American Association of Endocrine Surgeons April 2011, Houston TX
- 33. Morales-Garcia D, Nagarkatti S, Bhojraj TS, Gaz RD, Lubitz C, Randolph G, Stephen AE, Sadow PM, Hodin RA and **Parangi S:** Changes in surgery for Graves' disease over a 26 year period. Poster presentation at the American Association of Endocrine Surgeons April 2011, Houston TX
- 34. Phitayakorn R, Hodin RA, Gaz RD, Randolph G, **Parangi S,** Stephen AE, Morales-Garcia D, and Ehrenfeld JM: Factors associated with hemodynamic instability during total thyroidectomy. Abstract submitted to the American College of Surgeons 2011
- 35. Prescott JD., Sadow PM., Hodin RA, Le LP, MD, Gaz RD, Randolph GW., Stephen AE, **Parangi S**, Daniels GH, and Lubitz C: BRAF V600E status adds incrementally to current risk classifications systems in predicting papillary thyroid carcinoma recurrence Oral presentation at the American Association of Endocrine Surgeons, Iowa 2012
- 36. Phitayakorn R, Wanderer J, Ehrenfeld JM, Morales-Garcia D, Daniels GH, Carrie Lubitz C, Gaz RD, Stephen AE, Randolph G, **Parangi S**, Hodin RA, Graves' disease revisited, when is it safe to operate? Poster presentation at the American Association of Endocrine Surgeons, Iowa 2012
- 37. Phitayakorn R, Wanderer J, Carrie Lubitz C, Daniels GH, Ehrenfeld JM, **Parangi S**, Stephen AE, , Hodin RA, Phenoxybenzamine: Still a Good Match for Pheochromocytoma? Poster presentation at the American Association of Endocrine Surgeons, Iowa 2012
- 38. Prescott JD., Dhyani M, Samir A, Arellano H, Hodin RA, Gaz RD, Randolph GW., Randolph G, Zurakowski D, Finkelstein DM, **Parangi S**, and: Stephen AE, The

role of sheer wave ultrasound elastography in estimating cancer risk and determining the extent of surgery in patients with indeterminate thyroid nodules. Oral snapshot poster presentation at the American Association of Endocrine Surgeons, Iowa 2012

- 39. Gunda V, Bucur J, Varnau J, Lawler R., Khosravi-Far, R and **Parangi S:** TRAIL induced apoptosis is enhanced by inhibition of the MAPK and PI3K/AKT pathways in thyroid cancer cells. Oral presentation at The Academic Surgical Congress, New Orleans 2013
- 40. Gunda V, Cogdill AP, Wargo, JA and **Parangi S:** Potential role of 5- aza-2'-deoxycytidine induced MAGEA4 expression in immunotherapy for anaplastic thyroid cancer. Oral presentation at the American Association of Endocrine Surgeons, Chicago, 2013
- **41.** Duquette M, Sadow P, Fischer, A Priolo C, Hodin, RA, **Parangi S**, Lawler J and Nucera C: Investigating an orally available small-molecule inhibitor (Vemurafenib) of BRAF<sup>V600E</sup> in a novel preclinical model of human papillary thyroid cancer, Poster presentation at ASCO 2013
- 42. Lubitz C **Parangi S,** Faquin B and Sadow PM: Hobnail variant, a new aggressive subtype of papillary thyroid cancer. Poster presentation at the World Thyroid Congress, Toronto 2013
- **43.** Carrie C. Lubitz, Sareh Parangi, M. Jordana Bernasconi, Aislyn P. Schalck, Dennie T. Frederick, Hyunsuk Suh, Samuel E. Donovan, Lori Wirth, Ryan J. Sullivan, and David J. Panka. **Detection of Circulating BRAF**<sup>V600E</sup> **in Patients with Papillary Thyroid Carcinoma, American Thyroid Association, San Diego, October 2014**

#### **Narrative Report**

#### **Short Bio**

Dr. Parangi is a busy endocrine surgeon at Massachusetts General Hospital, Harvard Medical School in Boston, with a particular interest and expertise in thyroid and parathyroid tumors. She focuses her clinical efforts on endocrine surgery and applies her basic science knowledge and expertise to tumor progression in thyroid cancer. She performs over 300 endocrine surgery operations per year, many for thyroid cancer utilizing the latest technologies including recurrent laryngeal nerve monitoring. She has been in practice for 15 years. She has been a council member for the most prestigious organization of endocrine surgeons in the US, The American Association of Endocrine Surgeons, and a member of the American Thyroid Association. She has won numerous awards nationally and at Harvard Medical School for her research in the role of BRAF oncoprotein in thyroid cancer invasion. Her active research focuses on understanding why some patients with thyroid cancer do worse than others and how to help them. She has been one of the Boston surgeons named in Best Doctor and her excellent in both

research and her clinical expertise have earned her a national reputation. She is one of a handful of thyroid surgeons with expertise in molecular biology and has over 70 publications, many on thyroid cancer therapeutics in premier journal.

#### Research, Teaching and Clinical Contribution

My overall goal as a surgical faculty member at MGH and Harvard Medical School is to combine my training as a clinician/surgeon and scientist in order to treat patients with endocrine disorders using state of the art cutting edge intervention. In addition to providing the highest quality of care and performing excellent translational research, I strive to help the resident and clinical fellows learn how to apply research to everyday patient care.

My research interest in animal models of tumor progression and use of antiangiogenic/stromal modulators has been the cornerstone of my research interest. My research thus far has been supported by primary grants from the NIH in the form of a 5 year K08 Mentored Clinician Researcher Award, NIH R01 funding, as well as awards from the American College of Surgeons and American Thyroid Association. My research has focused on tumor angiogenesis, with special emphasis on molecular mechanisms of antiangiogenic drugs, the role of endothelial apoptosis in thyroid and pancreatic tumor progression and novel animal models of thyroid cancer. A new research area in my laboratory is to characterize how a common genetic mutation in aggressive thyroid cancer BRAF (V600E) leads to thyroid cancer cell invasion, migration and metastasis. We have started to characterize genomic and molecular changes that occur as a result of the BRAF mutation in human thyroid cancer cell in culture, our novel preclinical mouse model of thyroid cancer and in human urine and tissue samples. BRAF mutation appears to lead to direct changes in expression levels of various stromal molecules such as Thrombospondin-1 and integrins which then lead to the invasive and aggressive behavior of cells with this mutation. I have used a novel orthotopic model of aggressive thyroid cancer to test for the first time effects of novel inhibitors of mutant BRAF on the invasive behavior of these tumors, work which has been published in the Proceedings of the National Academy of Sciences and Oncologist. This research was the basis for NCI R01 funding granted to the laboratory. Our lab's work helped demonstrate how BRAF<sup>V600E</sup> mutation helps orchestrate the aggressive behavior of thyroid cancer cells and treatment with the selective BRAF<sup>V600E</sup>-inhibitor PLX4720 results in impressive decreases in tumor volume and metastasis in an orthotopic mouse model of ATC. These findings, combined with data from others, led to clinical trials with BRAF inhibitors such as Vemarufenib/Dabrafenib in patients with progressive PTC and ATC. Based on my lab findings, protocols have been developed in collaboration with the MGH Department of Pathology to evaluate all thyroid fine needle aspirations in addition to all surgically excised tissue at the MGH for this BRAF mutation and a large number of other mutations using hotspot mutational analysis. This new research effort will help understand whether known preoperative molecular markers are reliable predictors of lymph node involvement or recurrence in papillary thyroid cancer. Preoperative mutational analysis of thyroid tumor fine needle aspirations will help identify those with thyroid cancers that have a higher chance for aggressive clinical behavior and help discover novel thyroid cancerspecific molecular biomarkers, which in the future might allow "personalized" thyroid cancer surgery. We are hoping to complete or participate in a seminal randomized clinical trial looking at the role of central node dissection in thyroid cancer care and will add a molecular diagnostic component which should ultimately "personalize" thyroid cancer surgery and substantially improve patient care. This work exemplifies my dedication to translating bench work directly to the care of patients with endocrine diseases.

In addition, I have established the MGH Endocrine Tumor Tissue Repository in 2008 and the molecular diagnostics laboratory is has been combined with other translational research efforts at the MGH including the Endocrine Surgery Clinical Database under the auspices of the Codman Center for Clinical Effectiveness and basic science laboratory research to improve translational research in thyroid cancer. I have also been instrumental in helping target two innovative clinical approaches to thyroid and parathyroid patients with direct impact on the day to day care of patients at Harvard and nationally. In addition, during my time as surgical director of the BIDMC Thyroid Center I was instrumental in creating a "one stop shopping" model for treatment of the increasingly common "thyroid nodules". This model allowed physicians from different specialties with up to date knowledge of thyroid diseases but variable skills (such as endocrinologist, surgeons and radiologist) to be harnessed not only for superb patient care but also for graduate and undergraduate medical education. With this streamlined approach patient care improved and the collaborative curriculum/model helped make this helping make an interesting and sought after ambulatory clinical rotation for surgery/pathology/medical residents, cytology/endocrinology fellows and medical students. Lessons learned from this approach yielded innovative tools for curriculum development in other hospital settings where a high concentration of multidisciplinary teaching was employed.

As a surgical faculty I have always been involved with teaching HMS students during their surgical rotations as well as in formal surgical core curriculum courses. I am also deeply involved in teaching both surgical residents and fellows about endocrine surgery at a weekly endocrine surgery conference and as part of our ACS Score based teaching curriculum for residents. My interest in surgeon performed ultrasound has culminated in my direct involvement in development of a comprehensive nationally recognized head and neck ultrasound curriculum which has been used at the American College of Surgeons for teaching surgeons use of this technology for their practices. The ultrasound curriculum I helped develop has been used to teach both surgical residents and fellows both at BDIMC, MGH and nationally important basic ultrasound skills.